ASTMH 2018

67th Annual Meeting

28 October – 1 November 2018
New Orleans, USA

  • Nathalie Strub-Wourgaft, NTD Director – presentation on fexinidazole in a symposium on sleeping sickness elimination
  • Colin Forsyth, Chagas Epidemiologist, Sergio Sosa Estani, Head of Chagas Clinical Programme, Eric Chatelain, Head of Drug Discovery Programme – symposium on screening and diagnosis of Chagas disease
  • Poster and oral presentations on sleeping sickness, visceral leishmaniasis, Chagas, onchocerciasis, and mycetoma

Keystone Conference 2018

21st Century Drug Discovery and Development for Global Health

17-20 October 2018
Berlin, Germany

  • Nathalie Strub-Wourgaft, NTD Director – presentation on the new therapies for sleeping sickness
  • Charles Mowbray, Discovery Director – presentation on new orally active treatments for leishmaniasis

DNDi announces new Director of Neglected Tropical Diseases

Former DNDi Medical Director Dr Nathalie Strub-Wourgaft takes over leadership of NTD programme

DNDi is pleased to announce the appointment of Dr Nathalie Strub-Wourgaft as the new Director of Neglected Tropical Diseases. She will assume her new role as NTD Director and member of DNDi’s Executive Team as of 1 July 2018.

Onchocerciasis Network Meeting

3-4 October 2018
Kampala, Uganda

  • Sabine Specth, Head of Filariasis Clinical Programme – presentation of unmet medical need of onchocerciasis patients and Target Product Profile
  • Belén Pedrique, Medical Manager – presentation on access strategies for new treatments for onchocerciasis
  • Florent Mbo, HAT Platform Coordinator – presentation of the HAT Platform

Ninth EDCTP Forum

17-21 September 2018 
Lisbon, Portugal
DNDi – symposia on synergies between diagnostics and treatment studies for HAT and on data-sharing

R&D Portfolio Update March 2018: DNDi Sleeping sickness programme

Phase II/III study results confirmed that fexinidazole, DNDi’s first new chemical entity is safe and effective, and presents significant advantages over current treatment as it removes the need for lumbar puncture and systematic patient hospitalization. A regulatory dossier has been submitted to the European Medicines Agency for fexinidazole as the first all-oral treatment for sleeping sickness.

Geneva Health Forum

7th Edition: Precision Global Health in the Digital Age

10-12 April 2018
Geneva, Switzerland
Bernard Pécoul, Executive Director – plenary talk on emerging infectious diseases crisis
Digas Ngolo, Investigator Coordinator, DNDi Africa – parallel session on ehealth

ISNTD Festival 2018

27 March 2018
London, United Kingdom
Submission of the film “The Last Mile” to the ISNTD Festival Awards